According to a new report LAMEA Pneumonia Vaccines Market, published by KBV research, the LAMEA Pneumonia Vaccines Market would witness market growth of 10.1% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Pneumococcal Polysaccharide Vaccine (PPSV/PPV) Market by Region in 2018, growing at a CAGR of 11.2 % during the forecast period. The Argentina market is expected to witness a CAGR of 12.9% during (2019 - 2025). Additionally, The UAE market is expected to witness a CAGR of 12.2% during (2019 - 2025).
The Prevnar 13 market dominated the LAMEA Pneumonia Vaccines Market by Product Type in 2018, growing at a CAGR of 9 % during the forecast period. The Synflorix market is expected to witness a CAGR of 12.7% during (2019 - 2025). Additionally, The Pneumovax23 market is expected to witness highest CAGR of 14.5% during (2019 - 2025).
The Distribution Partner Companies market dominated the Saudi Arabia Pneumonia Vaccines Market by Distribution Channel in 2018, thereby, achieving a market value of $54.7 million by 2025, growing at a CAGR of 9.5 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 11.7% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/lamea-pneumonia-vaccines-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.
By Vaccine Type
By Product Type
By Sector
By Distribution Channel
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
